Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25302903 | 0.84 | LMNA (0.36) | LMNASMN1; SMN2HTR2AHRH1TDP1 | |
| Hydrochloric Acid SCHEMBL15719179 | 0.83 | TDP1 (0.37) | LMNASMN1; SMN2HTR2AHRH1TDP1 | |
| SCHEMBL25833224 | 0.81 | AOC3 (0.33) | LMNASMN1; SMN2HTR2AHRH1TDP1 | |
| SCHEMBL31068718 | 0.80 | PARP1 (0.36) | LMNASMN1; SMN2HTR2AHRH1TDP1 | |
| Hydrochloric Acid SCHEMBL15718924 | 0.80 | SLC6A2 (0.40) | LMNASMN1; SMN2TDP1SLC6A2SLC6A4 | |
| SCHEMBL25299772 | 0.80 | PARP1 (0.36) | LMNASMN1; SMN2HTR2AHRH1TDP1 | |
| SCHEMBL25261858 | 0.80 | AOC3 (0.44) | LMNASMN1; SMN2SLC6A2SLC6A4CYP3A4 | |
| Hydrochloric Acid SCHEMBL15719747 | 0.77 | RPS6KB1 (0.39) | LMNASMN1; SMN2TDP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL15719061 | 0.73 | AOC3 (0.46) | LMNASMN1; SMN2HTR2AHRH1TDP1 | |
| SCHEMBL25304228 | 0.72 | HTR2A (0.42) | HTR2AHRH1TDP1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2026-02-12 | — | — | US | disclosed |
| EP-4463453-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2024-09-19 | — | — | US | disclosed |
| CN-118541370-A | Azaindole derivatives and their use as ERK kinase inhibitors | AGV探索公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| WO-2023135233-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | WO | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| EP-4212531-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | LMNA 4684/4885SMN1; SMN2 4206/4885HTR2A 1968/4885 |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | BRAF, RAF1, NRAS | LMNA 3988/4885SMN1; SMN2 3745/4885HTR2A 4109/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | LMNA 4684/4885SMN1; SMN2 4206/4885HTR2A 1968/4885 |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | LMNA 4684/4885SMN1; SMN2 4206/4885HTR2A 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.